Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
4.540
0.00 (0.00%)
Aug 14, 2025, 9:02 AM - Market open
Agenus Employees
Agenus had 316 employees as of December 31, 2024. The number of employees decreased by 73 or -18.77% compared to the previous year.
Employees
316
Change (1Y)
-73
Growth (1Y)
-18.77%
Revenue / Employee
$321,854
Profits / Employee
-$524,310
Market Cap
144.66M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AGEN News
- 3 days ago - Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress - Business Wire
- 14 days ago - Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report - Business Wire
- 19 days ago - Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025 - Business Wire
- 5 weeks ago - Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3 - Business Wire
- 2 months ago - Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology - Business Wire
- 2 months ago - Agenus Announces Virtual Annual Shareholders Meeting - Business Wire
- 2 months ago - Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang - Benzinga
- 2 months ago - Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US - Business Wire